Eugene J. Koay

Mar 22, 2023 | onclive.com | Milind M. Javle |Eugene J. Koay |Rachna T Shroff |Flávio Rocha

Transcript:Milind M. Javle, MD: For our closing remarks, let me start with you, Dr Rocha. Given these strategies and findings in biliary tract cancer, what are you excited about and what are you looking forward to? Flavio G. Rocha, MD, FACS, FSSO: Thank you, Dr Javle. I’m very excited. All these developments that we see—in the advanced setting, the targeted setting, and the mutational landscape—I want to bring up front.

Mar 22, 2023 | onclive.com | Milind M. Javle |Eugene J. Koay |Rachna T Shroff |Flávio Rocha

Transcript:Milind M. Javle, MD: Inthe final segment of this program, we’re going to talk about targeted therapy. Dr Shroff, the last few years have been exciting, with 4 agents approved: infigratinib, pemigatinib, futibatinib, and ivosidenib. Perhaps there are more to come in the next year or 2. This is quite a staggering trajectory. Could you reflect on the FGFR space? There appears to be some redundancy and overlap in this space. What are you looking forward to?

Mar 15, 2023 | onclive.com | Milind M. Javle |Eugene J. Koay |Rachna T Shroff |Flávio Rocha

OncologyLiveOncology FellowsSupplements And Featured PublicationsAll Publications

Mar 8, 2023 | onclive.com | Milind M. Javle |Eugene J. Koay |Rachna T Shroff |Flávio Rocha

Transcript:Milind M. Javle, MD: I’m going to move on to systemic therapy for advanced and resectable disease. Dr Shroff, you led the SWOG S1815 trial. It was a pioneering trial because it was the first randomized phase 3 trial in this space. We’ve been eagerly anticipating the result. You gave a presentation [at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, ASCO GI].

Mar 8, 2023 | onclive.com | Milind M. Javle |Eugene J. Koay |Rachna T Shroff |Flávio Rocha

Transcript:Milind M. Javle, MD: Dr Rocha, the ultimate local therapy, liver transplant, is an accepted modality for the other liver cancer, HCC [hepatocellular carcinoma]. But I recall the original Milan criteria in NEJM [New England Journal of Medicine], which reflected on the fact that HCC used to be a contraindication for liver transplants sometime ago. There has been a sea change in cholangiocarcinoma as well. Could you comment on hilar cholangiocarcinoma and your experience there? Flavio G.